Top

International Journal of Clinical Oncology

Published in:

01-10-2013 | Original Article

Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma

Authors: Yosuke Yasuda, Yasuhisa Fujii, Takeshi Yuasa, Shinichi Kitsukawa, Shinji Urakami, Shinya Yamamoto, Junji Yonese, Shunji Takahashi, Iwao Fukui

Published in: International Journal of Clinical Oncology | Issue 5/2013

Abstract

Background

Bisphosphonates play an indisputable role in preventing skeletal-related events (SREs) secondary to bone metastases, and also have a direct effect on tumor cells. However, it remains unclear whether bisphosphonates improve overall survival (OS) for renal cell carcinoma (RCC) patients with bone metastases.

Methods

Between 1978 and 2010, a total of 45 patients who had RCC metastatic to bone and were classified as intermediate risk according to Memorial Sloan-Kettering Cancer Center criteria were included in this retrospective study. In this cohort, 23 patients received zoledronic acid (ZOL) treatment (ZOL-treated group) whereas the other 22 did not (non-ZOL-treated group). The primary endpoint was OS and the secondary endpoint was the SRE rate defined as the total number of SREs divided by the total years under study.

Results

For the cohort of 45 patients, the median OS from diagnosis of bone metastases was 27.2 months. Multivariate analysis showed that lower serum calcium (p = 0.0083) and ZOL treatment (p = 0.0013) were independent factors predicting longer survival. The ZOL-treated group had significantly longer OS than the non-ZOL-treated group (p = 0.0034). Patients in the ZOL-treated group experienced a lower SRE rate than patients in the non-ZOL-treated group (p = 0.0453). In particular, none of the patients in the ZOL-treated group developed spinal compression whereas 6 (28 %) in the non-ZOL-treated group did (p = 0.0479).

Conclusions

The current study indicates that ZOL not only reduces SREs but possibly improves OS in these patients.

Dekernion JB, Ramming KP, Smith RB et al (1978) The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol 120:148–152PubMed

Skinner DG, Colvin RB, Vermillion CD et al (1971) Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer. 28:1165–1177

Montie JE, Stewart BH, Straffon RA et al (1977) The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol. 117:272–275

Thompson IM, Shannon H, Ross G Jr et al (1975) An analysis of factors affecting survival in 150 patients with renal carcinoma. J Urol. 114:694–696

Coleman RE (2000) Management of bone metastases. Oncologist 5:463–470PubMedCrossRef

Corey E, Brown LG, Quinn JE et al (2003) Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 9:295–306PubMed

Rosen LS, Gordon D, Tchekmedyian S et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150–3157PubMedCrossRef

Kohno N, Aogi K, Minami H et al (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23:3314PubMedCrossRef

Saad F, Gleason DM, Murray R et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458–1468PubMedCrossRef

10.

Lipton A, Zheng M, Seaman J et al (2003) Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 98:962–969PubMedCrossRef

11.

Kijima T, Fujii Y, Suyama T et al (2009) Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate. BJU Int 103:620–624PubMedCrossRef

12.

Yuasa T, Urakami S, Yamamoto S et al (2011) Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis. Clin Exp Metastasis 28:405–411PubMedCrossRef

13.

Lin PP, Mirza AN, Lewis VO et al (2007) Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am 89:1794–1801PubMedCrossRef

14.

Althausen P, Althausen A, Jennings LC et al (1997) Prognostic factors and surgical treatment of osseous metastases secondary to renal cell carcinoma. Cancer 80:1103–1109PubMedCrossRef

15.

Jung ST, Ghert MA, Harrelson JM et al (2003) Treatment of osseous metastases in patients with renal cell carcinoma. Clin Orthop Relat Res 409:223–231PubMedCrossRef

16.

Kume H, Kakutani S, Yamada Y et al (2011) Prognostic factors for renal cell carcinoma with bone metastasis: who are the long-term survivors? J Urol 185:1611–1614PubMedCrossRef

17.

Szendroi A, Dinya E, Kardos M et al (2010) Prognostic factors and survival of renal clear cell carcinoma patients with bone metastases. Pathol Oncol Res 16:29–38PubMedCrossRef

18.

Toyoda Y, Shinohara N, Harabayashi T et al (2007) Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone. Eur Urol 52:163–168PubMedCrossRef

19.

Motzer RJ, Bacik J, Murphy BA et al (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289–296PubMedCrossRef

20.

Saito K, Tatokoro M, Fujii Y et al (2009) Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol 55:1145–1153PubMedCrossRef

21.

Guise TA (2008) Antitumor effects of bisphosphonates: promising preclinical evidence. Cancer Treat Rev 34:19–24CrossRef

22.

Ullen A, Schwarz S, Lennartsson L et al (2009) Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines. Scand J Urol Nephrol 43:98–103PubMedCrossRef

23.

Yuasa T, Sato K, Ashihara E et al (2009) Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model. Cancer Immunol Immunother 58:493–502PubMedCrossRef

24.

Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124PubMedCrossRef

25.

Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134PubMedCrossRef

26.

Zołnierek J, Nurzyński P, Langiewicz P et al (2010) Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases. J Cancer Res Clin Oncol 136:371–378PubMedCrossRef

27.

Sundaresan N, Galicich JH, Lane JM et al (1985) Treatment of neoplastic epidural cord compression by vertebral body resection and stabilization. J Neurosurg 63:676–684PubMedCrossRef

28.

Maranzano E, Latini P (1995) Effectiveness of radiation therapy without surgery in metastatic spinal cord compression: final results from a prospective trial. Int J Radiat Oncol Biol Phys 32:959–967PubMedCrossRef

29.

Leviov M, Dale J, Stein M et al (1993) The management of metastatic spinal cord compression: a radiotherapeutic success ceiling. Int J Radiat Oncol Biol Phys 27:231–234PubMedCrossRef

30.

Zelefsky MJ, Scher HI, Krol G et al (1992) Spinal epidural tumor in patients with prostate cancer. Clinical and radiographic predictors of response to radiation therapy. Cancer 70:2319–2325PubMedCrossRef

31.

Newman EM, Bouvet M, Borgehi S et al (2006) Causes of hypercalcemia in a population of military veterans in the United States. Endocr Prac 12:535–541CrossRef

32.

Lee C, Yang C, Lam K et al (2006) Hypercalcemia in the emergency department. Am J Med Sci 331:119–123PubMedCrossRef

33.

Vassilopoulou-Sellin R, Newman B, Taylor S et al (1993) Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer 71:1309–1312PubMedCrossRef

34.

Motzer RJ, Bander NH, Nanus DM (1996) Renal-cell carcinoma. N Engl J Med 335:865–875PubMedCrossRef

35.

Shinohara N, Abe T, Mochizuki T et al (2011) Is Memorial Sloan-Kettering Cancer Center risk classification appropriate for Japanese patients with metastatic renal cell carcinoma in the cytokine era? Urol Oncol (in press)

Title: Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma
Authors: Yosuke Yasuda
Yasuhisa Fujii
Takeshi Yuasa
Shinichi Kitsukawa
Shinji Urakami
Shinya Yamamoto
Junji Yonese
Shunji Takahashi
Iwao Fukui
Publication date: 01-10-2013
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 5/2013
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-012-0472-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2013

Glasgow Prognostic Score as a useful prognostic factor after hepatectomy for hepatocellular carcinoma

Comparison between cancer specialists and general physicians regarding the education of nurse practitioners in Japan: a postal survey of the Japanese Society of Clinical Oncology

Docetaxel in combination with estramustine and prednisolone for castration-resistant prostate cancer

Endoscopic evaluation of primary tumor response in patients with metastatic colorectal cancer treated by systemic chemotherapy

Influence of hospital surgical volume of radical prostatectomy on quality of perioperative care

Biological and molecular aspects of lymph node metastasis in gastro-intestinal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer